US-based oncology firm Umoja Biopharma has broken ground on a new manufacturing facility in Louisville, Colorado, the US.
The new 146,000ft2 facility is being constructed for manufacturing the company’s CAR T immunotherapies for cancer patients.
Go deeper with GlobalData
It will include labs, offices, and manufacturing space for the production of lentiviral vector. The facility will also help to overcome the crucial production barriers to provide effective and accessible cancer treatments, stated the firm.
The first manufacturing of clinical materials at the facility is anticipated to commence in the first quarter of 2023.
Launched in November last year, Umoja Biopharma uses its proprietary integrated technologies to reprogramme immune cells in vivo to develop new immunotherapies to treat solid tumours and hematologic malignancies.
Umoja Biopharma co-founder and CEO Andy Scharenberg said: “Manufacturing is a critical strategic component of Umoja’s approach to delivering the future of cancer immunotherapies, ensuring our treatments are widely accessible in a timely way and at a reasonable cost – all barriers that have long held the landscape of CAR T treatments back.
“Our facility in Colorado represents a significant investment into our commitment to bring novel therapies to cancer patients, as well as in how those therapies are produced, stored, and distributed.
“This facility will substantially enhance our company’s vector manufacturing, process development, and formulation capabilities, and we are extremely proud to announce the groundbreaking as the first step in bringing these capabilities online.”
In June, the company also closed on an oversubscribed $210m Series B financing round, which was co-led by SoftBank.
———————————————————————————————————————
Umoja Biopharma begins construction on new manufacturing facility in Louisville, Colorado. Credit: Hands off my tags! Michael Gaida from Pixabay.
